SMSPHARMA

- The 38th Annual General Meeting (AGM) for the financial year ended March 31, 2026, originally scheduled for Wednesday, September 23, 2026, will now be held on Tuesday, September 29, 2026. - The Record Date for determining dividend eligibility has been revised from Wednesday, September 16, 2026, to Tuesday, September 22, 2026. - The Book Closure period will be from Wednesday, September 23, 2026, to Tuesday, September 29, 2026.

- SMS Pharmaceuticals Limited issued intimation on Tax Deduction at Source (TDS) on the recommended final dividend of ₹0.40 per equity share for FY 2025-26. - The dividend is subject to approval at the 38th AGM on September 23, 2026, with the Record Date set as September 16, 2026. - Shareholders are required to submit relevant tax documents by September 09, 2026, for appropriate TDS calculation.

- Consolidated Revenue ₹207.0 Cr vs ₹196.1 Cr (▲6% YoY) - EBITDA ₹40.95 Cr vs ₹39.37 Cr (▲4% YoY) - PAT ₹20.20 Cr vs ₹18.72 Cr (▲8% YoY) - EBITDA Margin 20% vs 20% (Stable YoY)

- Consolidated Revenue ₹20,696.49 Lakhs vs ₹19,604.71 Lakhs (▲5.57% YoY) - EBITDA ₹4,269.53 Lakhs vs ₹3,996.22 Lakhs (▲6.84% YoY) - PAT ₹2,020.10 Lakhs vs ₹1,871.47 Lakhs (▲7.94% YoY) - EBITDA Margin 20.63% vs 20.38% (▲25bps) - The Board re-appointed Mr. Ramesh Babu Potluri as Chairman & Managing Director for five years effective October 1, 2026. - Approved a loan of up to ₹50 Crores to subsidiary SMS Peptides Private Limited, subject to shareholder approval. - The 38th Annual General Meeting (AGM) for FY2025-26 is scheduled for September 23, 2026.

- Consolidated Revenue ₹206.96 Cr vs ₹196.05 Cr (▲5.6% YoY) - EBITDA ₹40.95 Cr vs ₹39.37 Cr (▲4.0% YoY) - PAT ₹20.20 Cr vs ₹18.71 Cr (▲7.9% YoY) - EBITDA Margin 19.78% vs 20.08% (▼30bps) - Board approved the re-appointment of Mr. Ramesh Babu Potluri as Chairman & Managing Director for 5 years (Oct 1, 2026 - Sept 30, 2031). - Approved a loan up to ₹50 Cr to subsidiary SMS Peptides Private Limited, subject to shareholder approval. - The 38th Annual General Meeting (AGM) is scheduled for September 23, 2026, with September 16, 2026, fixed as the Record Date for dividend eligibility.

- Consolidated Revenue ₹206.96 Cr vs ₹196.05 Cr (▲5.56% YoY) - EBITDA ₹40.95 Cr vs ₹39.37 Cr (▲4.01% YoY) - PAT ₹20.20 Cr vs ₹18.71 Cr (▲7.96% YoY) - EBITDA Margin 19.79% vs 20.08% (▼29bps) - The 38th Annual General Meeting (AGM) for FY 2025-26 is scheduled for September 23, 2026. - Mr. Ramesh Babu Potluri re-appointed as Chairman and Managing Director for 5 years effective October 01, 2026. - Approved a loan up to ₹50 Crores to subsidiary SMS Peptides Private Limited, subject to shareholder approval.

- Consolidated Revenue ₹206.96 Cr vs ₹196.05 Cr (▲5.57% YoY) - EBITDA ₹42.70 Cr vs ₹39.96 Cr (▲6.84% YoY) - PAT ₹20.20 Cr vs ₹18.71 Cr (▲7.94% YoY) - EBITDA Margin 20.46% vs 20.32% (▲14bps)

- Consolidated Revenue ₹20,696.49 Lakhs vs ₹19,604.71 Lakhs (▲5.6% YoY) - EBITDA ₹4,095.09 Lakhs vs ₹3,936.91 Lakhs (▲4.0% YoY) - PAT ₹2,020.10 Lakhs vs ₹1,871.47 Lakhs (▲7.9% YoY) - EBITDA Margin 19.78% vs 20.08% (▼30bps) - Board approved the re-appointment of Mr. Ramesh Babu Potluri as Chairman and Managing Director for five years from October 1, 2026, subject to shareholder approval. - Approved a loan not exceeding ₹50 Crores to subsidiary SMS Peptides Private Limited, subject to shareholder approval. - The 38th AGM is scheduled for September 23, 2026, with September 16, 2026, as the record date for dividend eligibility for FY 2025-26.